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PPM. These charges averaged about $14 PPM (P = 0.069)
and $9 PPM (P = 0.231) lower than those of risperidone
and olanzapine, respectively, a savings of 2%–3% based
on a $526 PPM mean charge. Differences in non-
antipsychotic mental health care charges PPM among
bipolar patients treated with risperidone, olanzapine, or
quetiapine were largely explained by differing patient and
treatment characteristics rather than the antipsychotic
used. After dosage levels were standardized, however,
olanzapine was associated with signiﬁcantly higher drug
acquisition costs than those of risperidone and quetiap-
ine (57% and 49% respectively; P < 0.01). Although the
difference in drug charges between risperidone and que-
tiapine was not statistically signiﬁcant, quetiapine was
associated with lower PPM resource utilization. CON-
CLUSION: Quetiapine appears to be associated with
modestly lower non-antipsychotic mental health resource
use compared to risperidone and olanzapine for treatment
of bipolar disorder.
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OBJECTIVE: This study compared treatment patterns for
bipolar disorder (BP) patients (recognized and unrecog-
nized) to those of major depression disorder (MDD)
patients without a BP claim (non-BP) during the obser-
vational period. METHODS: An employer administrative
claims database (covering several managed care health
plans from 1998–2001) was used to identify 11,464
patients diagnosed with MDD and initially treated with
antidepressants (AD). Of these, unrecognized BP (UBP)
patients received their initial BP diagnosis and/or mood
stabilizer (MS) prescription after AD initiation, while rec-
ognized BP (RBP) patients had these records on/before
AD initiation. Induced BP patients were deﬁned as those
manifesting mania within six months after starting AD.
RESULTS: BP patients accounted for 6.8% of the
research sample (3.7% UBP and 3.1% RBP). Induced BP
represented 6.6% of all BP patients. RBP patients had a
slightly lower rate of induction (6.2%) than UBP patients
(6.9%). The use of combination therapies varied in the
non-BP, UBP, and RBP patients (11%, 32%, and 43%,
respectively) (all pairwise p < 0.01). The use of MS was
less frequent among UBP than RBP patients (14% and
34%, respectively) (p < 0.0001). CONCLUSIONS: A
substantial number of AD-treated MDD patients could be
classiﬁed as bipolar (either RBP or UBP), and were at risk
for induction of mania. RBP and UBP patients initiated
with more combination therapies, as compared to Non-
BP patients. MS use increased when BP was recognized.
More effort is needed to quickly diagnose and effectively
treat BP patients.
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OBJECTIVES: A Markov model was developed to deter-
mine costs and outcomes of one year of antipsychotic
treatment for patients with schizophrenia. METHODS:
The model simulated a 4-armed, randomized, parallel,
12-month observational study of 2000 inpatients and
2000 outpatients initiating treatment on ziprasidone (Z),
risperidone (R), olanzapine (O), or haloperidol (H).
Equivalent efﬁcacy between treatments was assumed;
however, relapse rates on haloperidol were adjusted to be
consistent with Csernansky et al. 2002. Weighted aver-
ages were used for published treatment-emergent adverse
event rates for akathesia (Z = 7.9, R = 15.1, O = 7.8, H
= 20.8), other extrapyridimal symptoms (Z = 11.5, R =
9.0, O = 11.6, H = 26.7), weight gain (Z = 10.0, R = 14.8,
O = 28.2, H = 11.0), and prolactin-related side effects (Z
= 2.2, R = 11.2, O = 5.2, H = 3.0) to estimate tolerabil-
ity, concomitant medication use, treatment changes, 
non-compliance, and relapse. Costs for inpatient care,
sub-acute chronic care, and outpatient visits were based
on published private and public medical claims databases.
Medication costs were $170.63/month (Z = 120mg/d),
$242.61/month (R = 4.8mg/d), $344.17 (O = 13.2mg/d),
and $6.72 (H = 15mg/d) (RedBook 2002). Outcome mea-
sures included days in acute care, total direct medical
costs, and incremental costs. RESULTS: Because of
greater tolerability, estimated days in acute care were
lowest for ziprasidone (42.4) when compared to olanza-
pine (42.8), risperidone (43.1), or haloperidol (53.6). Due
to lower estimated days in acute care and lower mainte-
nance treatment drug costs, estimated annual total health-
care costs for each drug cohort (n = 1000 patients per
cohort) were lowest for those patients initiating treatment
with ziprasidone vs. risperidone (+$787,000), olanzapine
(+$964,000), or haloperidol (+$4,210,000). Sensitivity
analyses to changes in model assumptions for adverse
event, adherence, and relapse rates, and healthcare 
costs were robust to these conclusions. CONCLUSION:
Ziprasidone has an adverse event proﬁle distinct from
those of other atypical antipsychotics and lower pharma-
ceutical acquisition costs, which potentially lead to
improved outcomes and lower total direct costs.
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